Hot of the Press: Lopinavir–Ritonavir NOT Effective in Severe COVID19 NEJM
Dr. Baliga's 'Podkasts for Curious Docs'
Release Date: 03/18/2020
Dengue Blocked, Viral Load Dropped, Hope Unlocked--High-Dose Mosnodenvir Delivers 💊🚀🛡️
Dr. Baliga's 'Podkasts for Curious Docs'
Thrilled to see a major step forward in dengue prevention! 🦟💊 A new NEJM study reports that daily mosnodenvir, a first-in-class antiviral targeting the NS3–NS4B interaction, significantly reduced DENV-3 viral load and prevented infection in a controlled human challenge model. 📉🧬 It’s early, but the results offer real hope for a long-awaited oral dengue prophylaxis—with encouraging safety, strong PK, and dose-dependent efficacy. 🚀🌍 Exciting moment for global infectious-disease innovation and antiviral development. 🙌✨
info_outline
Storms, Syncope, Survival 🌩️😵💫❤️ — Long QT Syndrome update
Dr. Baliga's 'Podkasts for Curious Docs'
Delighted to share a concise update on the latest NEJM review of Long QT Syndrome 🫀📘 — a masterful synthesis by Schwartz & Crotti that reframes how we recognize risk, personalize therapy, and prevent sudden death in this genetically mediated disorder. The piece highlights ion-channel biology, gene-specific triggers, the impact of modifier genes, and the effectiveness of a tiered therapeutic approach including beta-blockers, mexiletine, and left cardiac sympathetic denervation ⚡️🧬🛡️. For clinicians and trainees, it’s a compelling reminder that precise...
info_outline
Dr RR Baliga's Philosophical Discourses: Gottfried Wilhelm Leibniz (Germany, 1646–1716 CE) – Monadology
Dr. Baliga's 'Podkasts for Curious Docs'
🧠✨ Leibniz: Harmony, Logic, and the Birth of the Digital Mind Celebrating Gottfried Wilhelm Leibniz — the mathematician-philosopher who co-created calculus, invented binary arithmetic, and envisioned a world stitched together by pre-established harmony. His Monadology reads like proto-systems theory, and his binary system is the quiet ancestor of every computer we use today. For clinicians and scientists, his legacy whispers: 🔹 Seek the sufficient reason behind every pattern 🔹 Value multiple perspectives — every “monad” reflects a different truth 🔹 Build...
info_outline
Genes, Environment, Development 🧬🌿🧠— A 2025 Perspective on Autism
Dr. Baliga's 'Podkasts for Curious Docs'
🧬 New insights into autism: A 2025 JCI Viewpoint highlights how hundreds of genes, polygenic risk, and specific environmental factors converge during fetal brain development to shape autism likelihood. 🧠 Early biomarkers—from infant MRI and ERPs to machine-learning models using EHR data—are accelerating earlier, more tailored interventions. 🌱 Advances in gene therapy, IGF-1 pathways, and proteomics offer emerging therapeutic possibilities. 🤝 Centering autistic voices remains essential as precision approaches evolve.
info_outline
Numbness • Nerves • Nuance 🦶⚡🧠 — Decoding Peripheral Neuropathy
Dr. Baliga's 'Podkasts for Curious Docs'
🔍 Peripheral Neuropathy: What Clinicians Should Know 🧠⚡ Peripheral neuropathy affects ~1% of adults worldwide, with diabetes accounting for more than half of all cases. The JAMA review highlights why length-dependent patterns dominate, how metabolic stress injures long axons first, and why sensory symptoms outpace motor loss. Evidence-based evaluation still begins with glucose testing, vitamin B12 with methylmalonic acid, and serum protein electrophoresis. First-line therapies for neuropathic pain — gabapentin, pregabalin, duloxetine, and tricyclics — offer meaningful...
info_outline
Stroke Risk, Stent Benefit, Surgical Uncertainty 🧠✨🔧
Dr. Baliga's 'Podkasts for Curious Docs'
New NEJM insights on asymptomatic carotid stenosis 🧠🔍 The CREST-2 trials offer a landmark update: intensive medical therapy remains the cornerstone, while carotid stenting shows selective benefit when performed by expert operators. Endarterectomy, however, provides no significant advantage over modern medical management. With stricter blood-pressure and LDL targets, plus expanding use of PCSK9 inhibitors, the future of stroke prevention is increasingly precision-driven, medically optimized, and patient-centered. 💊📉✨ A thoughtful read for all involved in...
info_outline
UPFs, Diets, Disease: The Global Drift 🍔➡️🌍➡️⚠️
Dr. Baliga's 'Podkasts for Curious Docs'
The new Lancet Series on ultra-processed foods offers a striking insight: as UPFs rise globally, traditional whole-food diets decline—bringing nutrient imbalance, overeating, toxic exposures, and hyper-palatable formulations that quietly reshape health trajectories. 🍔➡️⚠️ Across more than 100 prospective studies and multiple trials, higher UPF intake consistently links to obesity, type 2 diabetes, cardiovascular disease, kidney disease, depression, and higher all-cause mortality. 📉🩺 The message is clear: reducing UPF consumption isn’t a wellness...
info_outline
Groceries, Guidance, Gains 🛒📞📉 — How DASH Delivery Lowers Blood Pressure
Dr. Baliga's 'Podkasts for Curious Docs'
Home-delivered DASH-patterned groceries paired with dietitian counseling meaningfully lowered blood pressure and LDL cholesterol among Black adults living in food deserts 🥗📉—as demonstrated in the GoFresh randomized trial (JAMA). An accompanying editorial highlights why future “food-as-medicine” programs must prioritize underconsumed, health-promoting foods and align with modern evidence favoring higher-fat DASH/Mediterranean patterns 🌱🫒. A powerful reminder: the right groceries can be therapeutic.
info_outline
Hemodialysis, Cardiovascular Burden, Therapeutic Hope 🩺❤️🌊 — Can Omega-3 Fatty Acids Bend the Risk Trajectory?
Dr. Baliga's 'Podkasts for Curious Docs'
🩺 New insights in hemodialysis care. A major New England Journal of Medicine study reports that daily supplementation with long-chain omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) led to a 43% reduction in serious cardiovascular events among adults receiving maintenance hemodialysis. 🐟💙 In a population where traditional cardioprotective therapies often fall short, these findings open a fresh path for investigation — and perhaps, future practice. 📉🔬 A confirmatory trial will be essential, but the signal is compelling. 🌅
info_outline
💊 Oral, Potent, Proven — Enlicitide Redefines LDL Control
Dr. Baliga's 'Podkasts for Curious Docs'
🚀 A milestone moment in lipid therapeutics! The new JAMA trial on the oral PCSK9 inhibitor Enlicitide reports a ~60% reduction in LDL-C, with parallel decreases in ApoB and Lp(a)—all on top of maximally tolerated statin therapy. For individuals with heterozygous familial hypercholesterolemia (HeFH)—where reaching LDL targets remains a persistent challenge—this represents a major advance. An oral agent matching the potency of injectable PCSK9 inhibitors could reshape adherence, access, and long-term ASCVD prevention. 🌉💊 Safety was comparable to placebo, and effects...
info_outlineHot of the Press: Lopinavir–Ritonavir NOT Effective in Severe COVID19 NEJM March 18, 2020
Dr RR Baliga's 'Got Knowledge Doc' Podcasts for Physicians
Not Medical Advice or Opinion